Cost figures in this article reflect the most recent verified data from CMS, NIDA, and published treatment studies; medication-assisted treatment annual estimates originate from NIDA’s published per-patient figures, and market price ranges reflect 2024–2026 reporting. This is financial and educational information, not medical advice — treatment decisions should be made with a licensed clinician.
TL;DR — Quick Verdict
- Program intensity drives price more than anything else: standard outpatient runs $1,400–$10,000 for 30 days, while residential treatment runs $5,000–$30,000 for the same stretch.
- Medical detox is billed separately at roughly $250–$800 per day, so a 5–7 day stay adds $1,250–$5,600 before rehab even begins.
- Medication-assisted treatment is the cost outlier in the other direction: NIDA puts methadone at $6,552 per year, buprenorphine at $5,980, and naltrexone at $14,112.
- Residential vs. intensive outpatient: for moderate substance use disorder, IOP delivers comparable evidence-based care at roughly one-third to one-half the total cost.
- Under the ACA and federal parity law, substance use treatment is a required benefit on virtually all marketplace and employer plans — verify your specific plan’s network and prior-authorization rules before committing.
A single month of residential addiction treatment can cost more than a used car — and for adolescent care, a NIDA-funded study led by researchers at Oregon Health & Science University found the average quoted price for a month’s residential stay topped $26,000. That number shocks families precisely because most people never price addiction treatment until they urgently need it, when comparison shopping feels impossible. The gap between the cheapest and most expensive path to recovery is enormous: two people with the same diagnosis can pay $5,980 a year or $60,000 a year depending entirely on which program type they enter. This article breaks down what each level of care actually costs in 2026 — detox, residential, partial hospitalization, intensive outpatient, standard outpatient, and medication-assisted treatment — using figures from the National Institute on Drug Abuse, the Centers for Medicare & Medicaid Services, and the American Society of Addiction Medicine. You’ll see where the money goes, which programs offer the best value for a given severity, and how insurance parity rules change your real out-of-pocket exposure. Providers like American Addiction Centers and Hazelden Betty Ford anchor the private-pay market, but the pricing logic applies everywhere.
What Each Program Type Costs in 2026
Addiction treatment is not one product. It’s a continuum, and every step up in intensity raises the price. The single most useful thing you can do before calling a facility is understand where the level you need sits on that continuum — because a residential quote for someone who only needs intensive outpatient care wastes thousands of dollars.
Here’s how the main program types break down on cost. Detox and residential figures reflect aggregated market reporting; medication-assisted treatment figures come directly from NIDA’s published per-patient estimates.
Sources: National Institute on Drug Abuse per-patient medication estimates; aggregated market reporting for detox and facility care. Medication figures verify at nida.nih.gov.
Notice the pattern: the round-the-clock programs cost the most per day, and medication-assisted treatment — despite running an entire year — often costs less than a single month of residential care. That inversion surprises people, and it’s the foundation of every smart cost decision in addiction treatment.
Why the Same Diagnosis Produces Wildly Different Bills
Consider two people, both diagnosed with moderate alcohol use disorder in the same city. One enters a 30-day residential program at a private facility and pays $28,000. The other enrolls in a structured intensive outpatient program three evenings a week and pays around $6,000 for the same month. Neither made a mistake — but the four-fold gap comes down to a handful of variables that facilities rarely explain upfront.
Level of care is the biggest lever. The American Society of Addiction Medicine organizes treatment on a scale from 0.5 to 4.0, where each decimal step reflects a jump in staffing, medical oversight, and housing. Standard outpatient sits at Level 1.0; intensive outpatient at 2.1; partial hospitalization at 2.5; residential at 3.1 through 3.5; and medically managed inpatient at 3.7 to 4.0. Every step up adds nursing hours, physician coverage, and — critically — a bed and meals. Housing alone accounts for a large share of the residential premium.
Ownership structure matters too. Two residential programs in the same market can quote prices differing by $10,000 or more for a 30-day stay, driven by staff-to-client ratios, for-profit versus nonprofit status, whether aftercare is bundled or referred out, and how much of the program is unbundled into add-on charges. A facility advertising a low base rate may bill detox, medication management, and lab work separately — so the sticker price and the final invoice can diverge sharply. Understanding how medication management visits are billed is one of the most overlooked parts of comparing quotes.
Residential vs. Intensive Outpatient: Which Is Better for Moderate Substance Use Disorder?
This is the decision most families actually face, because true medical necessity for 24-hour residential care is narrower than the marketing suggests. Residential treatment locks in housing, constant supervision, and full separation from triggers — genuinely valuable for severe cases, unstable housing, or dangerous withdrawal risk. But it charges for every one of those hours.
Intensive outpatient delivers the same evidence-based therapies — cognitive behavioral therapy, group counseling, relapse prevention, medication management — for 9 to 19 hours per week while the person lives at home and often keeps working. A NIDA Clinical Trials Network analysis of new opioid use disorder diagnoses found that inpatient detox and rehabilitation pathways carried roughly 2.3 times the initial 90-day cost of no treatment, while outpatient and medication pathways cost substantially less than inpatient care over the same window. Lower price did not mean lower effectiveness for the appropriately matched population.
The math is stark. A 30-day residential stay averaging $15,000–$28,000 compares against an IOP course near $3,000–$10,000 for comparable clinical contact hours. For someone with stable housing, a supportive home environment, and no acute withdrawal danger, the outpatient route can cut total cost by half or more without sacrificing quality of care.
Verdict
For moderate substance use disorder with stable housing and no acute medical withdrawal risk, intensive outpatient is the better value — comparable evidence-based care at roughly one-third to one-half the cost of residential treatment. Reserve residential care for severe cases, dangerous withdrawal, co-occurring conditions requiring 24-hour monitoring, or home environments that undermine recovery. Match the level of care to clinical need, not to the facility with the best brochure.
Medication-Assisted Treatment: The Cost Story Nobody Expects
Data upends the assumption that effective addiction treatment must be expensive. For opioid use disorder, medication-assisted treatment is both the clinical gold standard and, over a full year, one of the cheapest paths to sustained recovery. NIDA’s published per-patient estimates put methadone maintenance — including daily visits, the medication itself, and integrated counseling — at $6,552 per year. Buprenorphine, with semiweekly visits, runs $5,980 annually. Extended-release injectable naltrexone is the pricey exception at $14,112, driven largely by the medication’s own cost.
Set that against residential care. A single month of inpatient treatment at $15,000 to $28,000 exceeds an entire year of methadone or buprenorphine maintenance. For people whose primary need is stabilization and relapse prevention rather than acute crisis housing, the annual-versus-monthly framing reveals how much money conventional program hierarchies can waste.
Insurance changes these numbers meaningfully. Medicare’s Opioid Treatment Program benefit reimburses bundled MAT services — CMS has set weekly bundle rates covering the drug, counseling, and toxicology testing — so many enrollees pay only cost-sharing. The provider who prescribes and manages the medication also affects the bill, since office-based buprenorphine through a physician can differ from a certified opioid treatment program’s bundled rate.
What Insurance Actually Covers — and Where Parity Breaks Down
Since 2014, mental health and substance use disorder treatment has been one of the ten Essential Health Benefits required in every individual and small-group marketplace plan under the Affordable Care Act. That means a compliant plan cannot simply decline to cover rehab. On top of that, the Mental Health Parity and Addiction Equity Act prohibits plans from imposing stricter financial requirements or treatment limits on addiction care than they apply to comparable medical and surgical care — copays, deductibles, visit caps, and prior-authorization rules all have to be comparable.
In 2024, the Departments of Labor, Health and Human Services, and Treasury finalized new rules requiring plans to conduct and document comparative analyses proving their addiction benefits aren’t more restrictive than medical benefits, with particular focus on network adequacy and out-of-network reimbursement. Enforcement, though, still leaves gaps. Narrow provider networks, aggressive medical-necessity denials, and prior-authorization hurdles routinely push families toward out-of-network care, where costs balloon.
The practical takeaway: coverage existing on paper is not the same as an in-network bed being available when you need it. Before committing, confirm the specific facility is in-network, ask what level of care is authorized and for how long, and understand your appeal rights. Families who understand how to appeal a benefit denial recover far more of their costs than those who accept the first “not medically necessary” letter. If cost is the barrier to any care at all, sliding-scale and low-cost options and SAMHSA-funded programs fill part of the gap.
What Most People Get Wrong About Treatment Costs
Expensive decisions cluster around a few predictable misunderstandings. Each one costs real money.
Mistake 1: Assuming the sticker price is the total. Many facilities quote a base program rate that excludes detox, medication, lab work, and psychiatric consultations. The consequence is a final bill thousands of dollars higher than expected. The fix: ask for an itemized quote and specifically confirm whether detox and medication management are bundled or billed separately.
Mistake 2: Choosing residential when outpatient would suffice. The instinct that “more intensive equals better” leads people to pay for 24-hour care they don’t clinically need. The consequence is spending $20,000-plus on housing and supervision that adds little clinical value for a stable patient. The fix: get an independent ASAM-based assessment before accepting a residential recommendation from a residential facility.
Mistake 3: Ignoring medication-assisted treatment on cost grounds — backwards. Some avoid MAT assuming ongoing medication is expensive. The consequence is bypassing the most cost-effective long-term option for opioid use disorder. The fix: compare a full year of MAT against even a single month of residential care before ruling it out.
Mistake 4: Paying out-of-network without appealing. Accepting the first denial and going out-of-network can triple costs. The fix: invoke parity protections and file a formal appeal, which frequently reverses medical-necessity denials.
Is Residential Treatment Worth It for You?
Worth is conditional, and the honest answer depends on clinical severity and life circumstances rather than budget alone. Residential treatment earns its premium when specific conditions apply — and wastes money when they don’t.
Residential care is likely worth the cost if you face dangerous withdrawal requiring medical monitoring, have relapsed repeatedly after outpatient attempts, live in an environment saturated with triggers or active substance use, or carry co-occurring psychiatric conditions that need 24-hour stabilization. In these situations the housing and supervision aren’t luxuries; they’re the mechanism of recovery, and the alternative is often a more expensive crisis.
Residential care is likely not worth the premium if you have stable, supportive housing, a manageable withdrawal risk, employment you’d need to abandon, and a moderate rather than severe disorder. For that profile, intensive outpatient plus medication-assisted treatment where appropriate delivers evidence-based care at a fraction of the cost. The decision should follow an ASAM-based clinical assessment — ideally from an evaluator who doesn’t profit from the level of care they recommend. Cost and clinical need align more often than the industry’s default toward inpatient care would suggest.
Frequently Asked Questions
How much does a 30-day rehab program cost without insurance?
Without insurance, a standard 30-day residential program typically runs $5,000 to $30,000, with private and luxury facilities at the top of that range. Standard outpatient for the same period costs $1,400 to $10,000. Medical detox is usually billed separately at $250 to $800 per day. SAMHSA-funded programs, Medicaid, sliding-scale fees, and state block grants can substantially reduce or eliminate these costs for those who qualify.
Is medication-assisted treatment cheaper than rehab?
Over a full year, usually yes. NIDA estimates methadone at $6,552 annually and buprenorphine at $5,980 — less than a single month of residential care, which can reach $30,000. Injectable naltrexone is the exception at $14,112 per year. For opioid use disorder specifically, MAT is both the clinical standard and often the most cost-effective long-term path when 24-hour crisis housing isn’t clinically required.
Does insurance have to cover addiction treatment?
Under the Affordable Care Act, substance use disorder treatment is one of ten Essential Health Benefits required on all individual and small-group marketplace plans since 2014. The Mental Health Parity and Addiction Equity Act further requires that addiction benefits not carry stricter limits than comparable medical care. Coverage exists — but network adequacy, prior authorization, and medical-necessity denials still create real out-of-pocket exposure, so verify your specific plan.
What is the cheapest effective addiction treatment?
For opioid use disorder, buprenorphine-based medication-assisted treatment at roughly $5,980 per year is among the most cost-effective evidence-based options, and insurance or Medicaid often reduces that further. For those who cannot afford private care, SAMHSA-funded community clinics, Medicaid providers, and state behavioral health agencies offer free or reduced-cost treatment, though eligibility rules and waitlists apply. Cheapest and effective are not mutually exclusive here.
How We Researched This Article
This analysis draws on primary and institutional sources for every cost figure. Medication-assisted treatment annual estimates — methadone at $6,552, buprenorphine at $5,980, and naltrexone at $14,112 — come from the National Institute on Drug Abuse’s published per-patient figures, which bundle medication, visits, and associated clinical services. Insurance and reimbursement figures for opioid treatment programs derive from the Centers for Medicare & Medicaid Services’ Opioid Treatment Program payment rate schedules. The level-of-care framework follows the American Society of Addiction Medicine’s continuum, spanning Levels 0.5 through 4.0.
Facility cost ranges for detox, residential, and outpatient care reflect aggregated market reporting from treatment-industry sources and published studies, including a NIDA-funded study led by Oregon Health & Science University researchers on adolescent residential treatment pricing. Coverage and parity information is drawn from the U.S. Department of Labor, the Department of Health and Human Services, and CMS guidance on the Affordable Care Act’s Essential Health Benefits and the Mental Health Parity and Addiction Equity Act, including the 2024 final rules.
These figures are a mix of measured (CMS reimbursement rates, NIDA per-patient estimates) and modeled or market-reported (facility price ranges, which vary widely by geography, ownership, and bundling). Where market ranges are wide, that width reflects genuine variation rather than imprecision. Point figures for individual facilities were unavailable and would require direct quotes. This research was last conducted in July 2026. Primary regulatory and clinical sources can be verified at the Centers for Medicare & Medicaid Services, the National Institute on Drug Abuse, and the U.S. Department of Labor. All figures were verified against named primary sources before publication.